Exabis Library
Welcome to the e-CCO Library!
DOP86: FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP86: Mirikizumab-induced upregulation of colonic transcripts correlates with improvements in stool frequency in a phase 2 study of patients with moderately to severely active Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP86: Risk for development of inflammatory bowel disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis: a review and meta-analysis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP86: Risk for development of inflammatory bowel disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis: a review and meta-analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP87 SUCNR1 a novel key protagonist in fistula development
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP87: Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP87: Characterization of pathologic fibroblast and macrophage cell populations in colonic Crohn’s Disease with spatial transcriptomics.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP87: Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP87: Multi-parameter data-sets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP87: Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP87: SUCNR1 a novel key protagonist in fistula development
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP87: SUCNR1 a novel key protagonist in fistula development
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP88 Visceral fat area correlates well with anti-TNFα drug levels and secondary loss of response in Crohn’s disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP88: Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP88: Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP88: Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM